AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with milk (first dose 500 mg or less)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with soy (first dose 500 mg or less)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with wheat (first dose 500 mg or less)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with peanut (first dose 500 mg or less)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with fish (first dose 500 mg or less)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with milk (first dose 250 mg)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with egg (first dose 250 mg)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with milk (first dose 100 mg)
Trial: 10719311
Drug: DBPCFC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC with egg (first dose 100 mg)
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with egg
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with milk
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with soy
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with wheat
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with peanut
Trial: 10719311
Drug: DBPCFC (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPCFC (final dose or open challenge) with fish
Trial: 10719311
Drug: First dose
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First dose reactions severity
Trial: 10719311
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of PST and RAST with dose and severity
Trial: 8658221
Drug: PSK or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK or OK‐432 (biological response modifiers) added to chemotherapy
Trial: 1329251
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UF) 15,000 units, three subcutaneous injections (Group 1)
Trial: 1329251
Drug: Parnaparin 6,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin 6,400 units, single injection (Group 2)
Trial: 1329251
Drug: Parnaparin 12,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parnaparin 12,800 units, single injection (Group 3)
Trial: 3862230
Drug: Sugar free
RxNorm normalized name: Laxmar Sugar Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar free chewing gum containing 0.25 mg fluoride
Trial: 31415087
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of fezolinetant twice daily for 12 weeks
Trial: 20839388
Drug: Codeine (p.o.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (p.o. 30 mg q.d.s., n = 8)
Trial: 20839388
Drug: Methylnaltrexone (s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone (s.c. 0.30 mg/kg, n = 16)
Trial: 20839388
Drug: Combined MNTX
RxNorm normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combined MNTX and codeine (same doses and routes, n = 16)
Trial: 10930153
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy including protease inhibitors (PI)
Trial: 10930153
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy including non-nucleoside reverse transcriptase inhibitors (NNRTI)
Trial: 10930153
Drug: Dual nucleoside
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual nucleoside therapy
Trial: 9058214
Drug: Limited intentional
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited intentional normovolemic hemodilution (LINH) during the prebypass period until a hematocrit of 34% was obtained, with succinyl-linked gelatin infusion (n = 39)
Trial: 3527407
Drug: levamisole, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole, 2.5 mg/kg, 2 days of each week in addition to chemotherapy
Trial: 26775184
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and fentanyl combined as a single solution (group 2, 55 patients)
Trial: 26775184
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and fentanyl administered separately (group 1, 57 patients)
Trial: 18479744
Drug: Extended-release metoprolol
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metoprolol succinate (n=4174)
Trial: 8238220
Drug: 5-fluorouracil (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (mean total dose, 24.8 mg; mean number of injections, 5.0 ± 1.3)
Trial: 2436011
Drug: 2.9 g
RxNorm normalized name: ZINC OXIDE 12.9 g in 100 g TOPICAL LOTION [UV Skin Recovery SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.9 g of the amylase inhibitor
Trial: 2436011
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g of the amylase inhibitor
Trial: 26081485
Drug: EAA mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA mixture with 20% L-Leucine (Group A)
Trial: 26081485
Drug: EAA mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EAA mixture with 40% L-Leucine (Group B)
Trial: 18433921
Drug: Lactobacillus casei
RxNorm normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus casei Shirota (6.5 x 10(9)) 3 times daily for 4 weeks
Trial: 20076952
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg orally for 5 days)
Trial: 11801578
Drug: AmBisome 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 3 or 5 mg/kg/day
Trial: 11801578
Drug: Abelcet 5
RxNorm normalized name: Abelcet 5 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelcet 5 mg/kg/day
Trial: 11801578
Drug: Lipid formulations
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid formulations (general)
Trial: 7869686
Drug: Initial injection
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial injection of diluted local anesthetic (1:10 with saline)
Trial: 27479106
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy (CBGT) with e-mail support
Trial: 27479106
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy (CBGT) without e-mail support
Trial: 24549763
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) with 1,000 impulses
Trial: 13677125
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g Owen Mumford monofilament sensory testing
Trial: 9346691
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin bolus (666 mU . kg‐1) followed by infusion at 500 mU.m‐2.min‐1 until 3 hours after portal vein unclamping.
Trial: 9346691
Drug: No exogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No exogenous insulin administered.
Trial: 27296819
Drug: Aclidinium 400
RxNorm normalized name: aclidinium 400 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium 400 μg/formoterol 12 μg
Trial: 24532007
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tideglusib
Trial: 24532007
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tideglusib
Trial: 15908835
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 10 mg once daily, with 10 mg weekly dose increases to a maximum of 30 mg/d
Trial: 10917210
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of a replication-defective adenoviral expression vector containing wild-type p53
Trial: 9347431
Drug: ondansetron 100
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron 100 mcg/kg
Trial: 9347431
Drug: droperidol 75
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: droperidol 75 mcg/kg
Trial: 9347431
Drug: metoclopramide 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 250 mcg/kg
Trial: 8191134
Drug: Miocamycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miocamycin (15 mg/kg/day bid per os)
Trial: 8191134
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (600,000 or 1,200,000 units, single injection)
Trial: 3083712
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally) with SNP
Trial: 24445685
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral n-acetyl cysteine twice daily
Trial: 22730694
Drug: Complex treatment
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex treatment group
Trial: 20556437
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine
Trial: 16167284
Drug: Tobramycin enhanced
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin enhanced viscosity ophthalmic solution (3 mg/mL) given twice daily (BID) for 7 days
Trial: 16167284
Drug: Tobramycin 0.3%
RxNorm normalized name: TOBRAMYCIN 0.3% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3% ophthalmic solution (3 mg/mL) given four times daily (QID) for 7 days
Trial: 10087016
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of caffeine consumed as a single dose in the morning
Trial: 10087016
Drug: Caffeine maintenance
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine maintenance doses of 100, 300, and 600 mg/day
Trial: 10087016
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg caffeine/day with lower doses (200, 100, 50, 25, and 0 mg/day)
Trial: 10087016
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day for 1, 3, 7, or 14 days
Trial: 7612769
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg intravenously (4 doses starting at induction of anaesthesia)
Trial: 7612769
Drug: Hyoscine transdermally
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine transdermally (patch placed behind the ear at 0600 h on the day of operation)
Trial: 28033244
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (100,000 units single oral dose)
Trial: 23903022
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg bolus followed by 1 mg·kg·h infusion (low dose)
Trial: 23903022
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg bolus followed by 16 mg·kg·h infusion (high dose)
Trial: 15899163
Drug: 105 mg
RxNorm normalized name: menthol 105 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg of elemental iron daily p.o.
Trial: 15899163
Drug: 105 mg
RxNorm normalized name: menthol 105 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 mg of elemental iron daily and 5 mg of folic acid daily p.o.
Trial: 15899163
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin supplements (control group)
Trial: 14565892
Drug: Treatment completers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment completers (N = 18)
Trial: 14565892
Drug: Follow-up (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up (6 months post-treatment)
Trial: 10037634
Drug: Beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene (42 mg, or 7000 micrograms retinol equivalents)
Trial: 8650042
Drug: d-penicillamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-penicillamine treatment
Trial: 1784628
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg miglitol
Trial: 30144629
Drug: Standard In-Office
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard In-Office Cognitive Processing Therapy (CPT)
Trial: 30144629
Drug: In-Home CPT
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-Home CPT (provider delivers treatment in participant's home)
Trial: 22244363
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (SUP)
Trial: 20102884
Drug: Plasminogen activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen activator inhibitor-1 (PAI-1) antigen
Trial: 17375984
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human porphobilinogen deaminase (P 9808) at doses of 0.5, 1, 2, and 4 mg/kg bodyweight
Trial: 16327349
Drug: Sprotte 24
RxNorm normalized name: BRUSSELS SPROUT
DrugBank: Brussels sprout (DB10642)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprotte 24 g atraumatic spinal needle
Trial: 9457145
Drug: Buprenorphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (4 or 12 mg)
Trial: 9457145
Drug: Buprenorphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (4 mg)
Trial: 9457145
Drug: Methadone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (20 or 65 mg)
Trial: 2649300
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nicardipine t.i.d.
Trial: 2649300
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide b.i.d.
Trial: 37848
Drug: MIF (melanocyte-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIF (melanocyte-stimulating hormone-release inhibiting factor) 200 mg i.v.
Trial: 30797746
Drug: Endobronchial coil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial coil treatment (QVM+)
Trial: 30797746
Drug: Endobronchial coil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial coil treatment (QVM-)
Trial: 15592334
Drug: AMG 531
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 531 (10.0 microg/kg, intravenous)
Trial: 15592334
Drug: AMG 531
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 531 (2.0 microg/kg, subcutaneous)
Trial: 15592334
Drug: AMG 531
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 531 (1.0 microg/kg, intravenous and subcutaneous)
Trial: 8831412
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pilsicainide
Trial: 30194618
Drug: Hysterosalpingogram (HSG)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hysterosalpingogram (HSG) vs Saline infusion sonohysterography (SIS)
Trial: 25701561
Drug: Intensive five-drug
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive five-drug cART regimen (raltegravir 400 mg and maraviroc 150 mg twice daily, plus tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Trial: 25701561
Drug: Standard triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple-drug cART regimen (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Trial: 25701561
Drug: Intensive five-drug
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive five-drug cART regimen
Trial: 25701561
Drug: Standard triple-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple-drug cART regimen
Trial: 10677921
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of 350 mg Euphyllin Retard at 8:00 A.M.
Trial: 10677921
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of 350 mg Euphyllin Retard at 8:00 P.M.
Trial: 1421063
Drug: Ephedrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (5 mg/dose)
Trial: 1421063
Drug: CaCl2 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCl2 (200 mg/dose)
Trial: 27689688
Drug: Navy beans
RxNorm normalized name: navy kidney bean allergenic extract
DrugBank: Kidney bean (DB10639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navy beans (NB) consumption (35 g/day)
Trial: 27689688
Drug: Rice bran
RxNorm normalized name: Rice bran
DrugBank: Rice bran (DB14361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice bran (RB) consumption (30 g/day)
Trial: 16115394
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) 250 microg bid for moderate asthma and 375 microg bid for severe asthma (Group G)
Trial: 16115394
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) 125 microg bid for moderate asthma and 125 microg in the morning, 250 microg in the evening for severe asthma (Group H)
Trial: 16115394
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) (Group G)
Trial: 16115394
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) (Group H)
Trial: 10802126
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg bid)
Trial: 29561511
Drug: Biannual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual treatment of children under 12 with azithromycin (20 mg/kg up to 1 g in adults)
Trial: 29561511
Drug: Annual treatment
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual treatment of everyone with azithromycin (20 mg/kg up to 1 g in adults)
Trial: 29561511
Drug: Biannual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual treatment of children under 12 with azithromycin
Trial: 21753160
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone (0.75 mg/kg/day)
Trial: 21753160
Drug: Weekend prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekend prednisone (10 mg/kg/wk)